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Prognostic Value of Ambulatory Blood Pressure
Monitoring in Refractory Hypertension
A Prospective Study
Josep Redon, Carlos Campos, Maria L. Narciso, Jose L. Rodicio, Jose M. Pascual, Luis M. Ruilope
Abstract—The objective of this study was to establish whether ambulatory blood pressure offers a better estimate of
cardiovascular risk than does its clinical blood pressure counterpart in refractory hypertension. This prospective study
assessed the incidence of cardiovascular events over time during an average follow-up of 49 months (range, 6 to 96).
Patients were referred to specialized hypertension clinics (86 essential hypertension patients who had diastolic blood
pressure .100 mm Hg during antihypertensive treatment that included three or more antihypertensive drugs, one being
a diuretic). Twenty-four-hour ambulatory blood pressure monitoring (ABPM) was performed at the time of entrance.
End-organ damage was monitored yearly, and the incidence of cardiovascular events was recorded. Patients were divided
into tertiles of average diastolic blood pressure during activity according to the ABPM, with the lowest tertile ,88 mm Hg
(LT, n529), the middle tertile 88 to 97 mm Hg (MT, n529), and the highest tertile .97 mm Hg (HT, n528). While
significant differences in systolic and diastolic ambulatory blood pressures were observed among groups, no differences
were observed at either the beginning or at the time of the last evaluation for office blood pressure. During the last
evaluation, a progression in the end-organ damage score was observed for the HT group but not for the two other groups.
Twenty-one of the patients had a new cardiovascular event; the incidence of events was significantly lower for the LT
group (2.2 per 100 patient-years) than it was for the MT group (9.5 per 100 patient-years) or for the HT group (13.6 per
100 patient-years). The probability of event-free survival was also significantly different when comparing the LT group
with the other two groups (LT versus MT log-rank, P,.04; LT versus HT log-rank, P,.006). The HT group was an
independent risk factor for the incidence of cardiovascular events (relative risk, 6.20; 95% confidence interval, 1.38 to 28.1,
P,.02). Higher values of ambulatory blood pressure result in a worse prognosis in patients with refractory hypertension,
supporting the recommendation that ABPM is useful in stratifying the cardiovascular risk in patients with refrac-
tory hypertension. (Hypertension. 1998;31:712-718.)
Key Words: blood pressure monitoring, ambulatory n hypertension, refractory n cardiovascular risk n prognosis
Hypertensive patients whose clinical BP remains persistentlyhigh despite being prescribed appropriate multiple medi-
cations present a relatively common clinical problem. These
patients, so-called resistant or refractory, account for 10% of
hypertensive subjects referred to specialized clinics and fre-
quently have changes in their medications, including the
addition of other antihypertensive drugs.1 Attempts have been
made to classify refractory hypertension according to its cause.
It may be due to a specific identifiable disorder (secondary
hypertension) associated with exogenous substances that raise
BP or interfere with the action of antihypertensive agents (ie,
nonsteroidal anti-inflammatory drugs), attributable to compli-
cating biological factors (obesity and hyperinsulinemia), ascrib-
able to inappropriate or inadequate treatment, or due to
noncompliance with a prescribed medical regimen. In many
cases, however, it is not possible to find a potentially correct-
able cause of the elevated BP, even though the patient’s
compliance to medication seems to be adequate.1
In some cases this may be the result of genuine refractory
hypertension, while interesting that in others it may be simply
the consequence of an exaggerated white-coat effect. For
instance, evaluation of these patients requires BP measure-
ments outside the clinical environment in order to exclude the
existence of the latter.2 Monitoring ambulatory BP with a
noninvasive device3,4 provides more representative values of
BP than clinic BP does, and the behavior of BP during the
activity and sleep periods is observable. Target-organ damage
in essential hypertension correlates better with ambulatory than
with clinical BP,5,6 and for any given value of clinical BP,
target-organ damage is directly related to the mean levels and
variability of ambulatory BP. Moreover, it has been claimed
that values obtained in 24-hour monitoring are better predic-
tors of cardiovascular risk than data obtained in casual
measurements.7–9
Published consensus has established that one of the major
uses for ABPM is in the evaluation of refractory hyperten-
Received August 4, 1997; first decision September 2, 1997; revision accepted September 29, 1997.
From the Hypertension Clinic, Hospital Clı´nico, University of Valencia (Spain) (J.R., M.L.N.); Hypertension Clinic, 12 de Octubre Hospital, Madrid
(C.C., J.L.R., L.M.R.); and Internal Medicine, Hospital of Sagunto (Spain) (J.M.P.).
Correspondence to Josep Redon, MD, Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Avda Blasco Iban˜ez 10, 46010
Valencia, Spain.
© 1998 American Heart Association, Inc.
712
 at SWETS SUBS SERV-#54225388 on May 18, 2010 hyper.ahajournals.orgDownloaded from 
sion.10–20 Despite agreement in the use of ABPM with refrac-
tory hypertensive subjects, no confirmatory data about the
prognostic value of ABPM in this group have been available
until now. To establish whether ambulatory BP offers a better
estimate of cardiovascular risk than do its clinical BP counter-
parts, we have conducted a prospective study assessing the
incidence of cardiovascular events over time in patients diag-
nosed as having refractory hypertension.
Methods
Selection of Study Participants
A group of 86 patients were included in the study. Patients were
recruited from the outpatient clinic of two hospitals (Hospital of
Sagunto and Hospital 12 de Octubre, Madrid) over a 68 month period
(January 1989 to December 1994). All patients who fulfilled the
inclusion criteria were invited to participate, and written consent was
obtained. The inclusion criteria were the following: (a) clinical
diastolic BP .100 mm Hg (Korotkoff phase V, sitting position) for
three visits at 1-month intervals during the same antihypertensive
treatment, which included three or more antihypertensive drugs, one
of them being a diuretic; (b) preserved renal function, glomerular
filtration rate estimated by endogenous creatinine clearance .60
mL/min per 1.73 m2. Patients with diabetes mellitus or with second-
ary hypertension were excluded. The presence of previous cardiovas-
cular events did not constitute an exclusion criteria in subjects
maintaining their normal physical and work activities.
At the beginning of the study all patients had a complete clinical
workup to rule out secondary hypertension and to assess the presence
of end-organ damage. Twenty-four ABPM were performed at the
time of entrance. End-organ damage was monitored yearly, and the
incidence of cardiovascular events during the time of follow-up was
recorded. A minimal 6-months of follow-up was required for being
included in the analysis.
Office and Ambulatory Blood
Pressure Measurements
BP was measured in a quiet environment with a mercury sphygmo-
manometer with the patient in a sitting position after 5 minutes of rest,
following the recommendations of the British Hypertension Society.21
SBP and DBP (Korotkoff phase I and phase V, respectively) repre-
sented in each visit the mean of three different readings measured at
5-minute intervals.
ABPM was performed with the use of an oscillometric monitor
(Spacelabs 90202 or 90207) on a regular working day, during the
normal intake of the usual antihypertensive treatment. Following the
standard protocol, recording began between 8:30 and 9 AM, with
readings every 20 minutes from 6 PM until midnight and every 30
minutes from midnight to 6 AM. Before starting the study, reliability
of BP values measured with the monitor were checked against
simultaneous measurements with a mercury sphygmomanometer.
Differences of ,5 mm Hg were allowed. Those patients with record-
ings showing an error rate in .25% of the total readings were
excluded from the study.
Different time periods were defined in the following manner for the
analysis of BP values obtained during monitoring: (a) the total 24
hours, (b) a day or activity period running from 8 AM until 10 PM, (c)
a night or sleep period running from midnight to 6 AM, and (d) hourly
periods over the 24 hours. The average of SBP, DBP, and mean blood
pressure were calculated for every one of the periods. The ratio
between the averages of BP during the day period and during the
night period, day/night ratio, was calculated as an estimate of circadian
variability.
Patients were divided into tertiles of average DBP during activity
according to the ABPM, with the LT ,88 mm Hg (n529), the MT
88 to 97 mm Hg (n529), and the HT .97 mm Hg (n528).
Clinical Score of End-Organ Damage
The presence of end-organ damage attributed to hypertension, esti-
mated at the beginning of the study and yearly, was reported as a
modification of a previously published score.22 This score was calcu-
lated with the use of data derived from each patient’s history, physical
examination, and laboratory investigations such as ECG, chest radio-
graph, fundus oculi, urinalysis, and plasma creatinine. History ques-
tions were asked to establish the presence (1 point) or absence (0
points) of ischemic heart disease, heart failure, cerebrovascular insuf-
ficiency, and peripheral arterial disease. The following ECG abnor-
malities were considered evidence of target-organ damage: (a) left
ventricular hypertrophy (Sokolow criteria) without (1 point) or with
strain (2 points); (b) other ECG abnormalities, such as signs of
infarction, resting ischemia, left bundle-branch block, ventricular
arrhythmias, and atrial fibrillation in absence of other possible causes (1
point). Abnormalities on chest radiograph considered evidence of
target-organ damage were (a) moderate, cardiothoracic index 0.50 to
055, (1 point) or (b) marked cardiac enlargement, cardiothoracic index
.0.55 (2 points). The abnormalities of the fundus were classified
according to the Keith-Wagener criteria: grade II (1 point) and grade
III or IV (2 points). Serum creatinine .132 mmol/L (1.5 mg/dL)
and/or proteinuria .1 g/24 hours scored 1 additional point. The total
score for an individual patient was the sum all item scores and ranged
from a minimum of 0 to a maximum of 12.
Follow-up of the Patients
After the initial evaluation, patients were followed in one of the
outpatient clinics and when needed during hospitalization periods by
one of the authors. Antihypertensive treatment was monitored by
means of frequent office BP measurements, and when appropriate
changes in the number, class, and dose of antihypertensive drugs
(diuretics, b-blockers, a-blockers, calcium channel blockers, angio-
tensin-converting enzyme inhibitors, and vasodilators) were made
according to clinical criteria (goal of BP control ,140/90 mm Hg) in
spite of whether treating physicians were or were not aware of the
ABPM results. A comparison of the incidence of new cardiovascular
events, fatal and nonfatal, between patient groups was made during the
follow-up. In subjects experiencing multiple nonfatal events, the
analysis included only the first event. Cardiovascular events included
myocardial infarction, angina pectoris, coronary revascularization,
stroke, transient ischemic attack, sudden death, aortoiliac occlusive
disease, progressive heart failure, and hypertensive emergency. Myo-
cardial infarction was diagnosed on the basis of at least two of three
standard criteria (typical chest pain, ECG QRS changes, and transient
elevation of myocardial enzymes by more than twofold the upper
normal laboratory limits). Angina pectoris was defined as chest pain
accompanied by typical ischemic changes in the ECG. Stroke was
diagnosed on the basis of rapid onset of localizing neurological deficit
lasting 24 hours or longer in the absence of any other process that
could explain the symptoms. Transient ischemic attack was defined as
any sudden focal neurological deficit that cleared completely in less
than 24 hours, based on a diagnosis made by a physician. Sudden death
was defined as a witnessed death that occurred within 1 hour after the
onset of acute symptoms, with no history of violence or accident
playing a role in the fatal outcome. Progressive heart failure was
defined as symptoms when appearing during the follow-up in patients
without previous heart failure symptoms. Hypertensive emergency
Selected Abbreviations and Acronyms
ABPM 5 ambulatory blood pressure monitoring
BP 5 blood pressure
CI 5 confidence interval
DBP 5 diastolic blood pressure
ECG 5 electrocardiograph
HT 5 highest tertile
LT 5 lowest tertile
MT 5 middle tertile
RR 5 relative risk
SBP 5 systolic blood pressure
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was defined as, and only considered applicable, when symptoms were
accompanied by papilledema in funduscopic examination.
Statistical Analysis
For each variable, values are expressed as mean6SD. Differences
between groups were sought by using ANOVA for continuous
variables and x2 for discontinuous variables. Two-way ANOVA was
used to analyze changes in the variables (BP and score) over time in
the two group of patients.
Event rates for new cardiovascular events, fatal plus nonfatal, during
the time of follow-up are presented as the number of events per 100
patient-years, based on the ratio of the observed number of events to
the total number of patient-years of exposure. Survival curves were
estimated with the Kaplan-Meier product-limit method, and differ-
ences between groups were estimated by the log-rank test. The Cox
proportional hazard model was used to assess the effect of the
prognostic factor on event-free survival. We tested the independent
significance of each ABPM tertile group. The covariates included
previous cardiovascular events (absent, present), age (,60 years, .60
years), sex, current smoking (absent, present), ECG criteria of left
ventricular hypertrophy (absent, present), office BP at beginning and
during follow-up, and average of daytime ambulatory SBP as a
continuous variable. Adjusted RR for the significant Cox model
factors were calculated and expressed along with the 95% CI.
Results
General Characteristics
Eighty-six patients (27 men and 59 women; mean age, 5369
years), all white, who met the inclusion criteria, were included
in the study. The principal clinical characteristics and BP values
of the patients in each group are shown in Table 1. No
differences in age, sex, or body mass index were observed
between groups. Five patients (17%) in the LT group, 6 (21%)
in the MT group, and 7 (25%) in the HT group had had at least
one previous cardiovascular event.
Blood Pressure at the Beginning of the Study
and at the End of the Follow-up Period
Office and ambulatory BP values are shown in Table 1. No
differences in office SBP and DBP were present among the
groups. Not only the mean values of both 24-hour ambulatory
SBP and DBP, but also those values obtained during day and
night periods were significantly higher in the HT group
(P,.001) than in the other groups. Differences between office
BP and the average of daytime ambulatory BP were
29.1624.1 mm Hg for SBP and 15.4612.2 mm Hg for DBP.
Only 6 (8.3%) of the subjects had a daytime ambulatory BP
higher than their office BP. The circadian pattern of BP in the
three groups is shown in Fig 1. The highest tertile group
exhibited the greatest average values of hourly SBP and DBP
throughout the day and night periods when compared with the
other groups (P,.01 for all hourly periods). No differences in
the day/night ratio as an estimate of circadian variability were
observed among the groups.
The values of office BP achieved at the time of final
evaluation were significantly lower than those observed at
baseline. The extent of BP reduction, however, did not differ
among the three groups for either the SBP (LT group,
17.1 mm Hg; 95% CI, 6.3 to 27.7; MT group, 16.4 mm Hg,
95% CI, 3.8 to 29.1; HT group, 14.5 mm Hg, 95% CI, 0.6 to
TABLE 1. General Characteristics: Office and Ambulatory BPs in Hypertensive Subjects
Grouped by Ambulatory BP
Lowest Tertile,
n529
(Daytime DBP
<88 mm Hg)
Middle Tertile,
n529
(Daytime DBP
88-97 mm Hg)
Highest Tertile,
n528
(Daytime DBP
>97 mm Hg)
Age, y 55.667.5 53.3611.4 50.868.4
Sex, M/F 11/18 8/21 6/22
Body mass index, kg/m2 28.363.9 28.164.0 28.363.7
Antihypertensive drugs, n 3.360.6 3.160.6 3.560.9
Office BP, mm Hg
SBP 174.8620.6 173.8620.3 182.2623.8
DBP 105.564.7 107.065.9 110.969.6
Ambulatory BP, mm Hg
Average 24-hour
SBP 129.6617.8 142.2612.3 161.2615.0
DBP 77.065.0 88.564.9 101.766.7
Average daytime (8 AM-10 PM)
SBP 132.1618.3 145.4612.1 165.1614.7
DBP 79.664.9 91.963.7 105.666.8
Average nighttime (midnight-6 AM)
SBP 121.8617.3 129.6617.5 145.9618.2
DBP 69.267.7 76.9612.3 89.6611.5
Day/night ratio
SBP 1.0960.09 1.1360.11 1.1360.11
DBP 1.1760.11 1.2160.16 1.1960.15
Values are mean6SD.
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28.3; P5NS) or for the DBP (LT group, 12.0 mm Hg, 95%
CI, 7.6 to 16.4; MT group, 9.7 mm Hg, 95% CI, 4.3 to 15.1;
HT group, 9.4 mm Hg, 95% CI, 1.8 to 17.0; P5NS). Office
DBP persisted at .100 mm Hg for 11 (38%) of the LT group,
12 (41%) of the MT group, and 14 (50%) of the HT group at
the last evaluation.
Clinical Score at the Beginning of the Study and
at the End of the Follow-up Period
At baseline, mean value of the clinical score was higher in the
HT group than in the other groups; however, this difference
did not attain statistical significance (LT group, 2.30, 95% CI,
1.45 to 3.14; MT group, 2.41, 95% CI, 1.50 to 3.33; and HT
group, 2.64, 95% CI, 1.82 to 3.47; respectively, P5NS).
A statistically significant progression of end-organ damage
was observed for the highest ambulatory BP group (3.70, 95%
CI, 2.82 to 4.58; P,.03), but not for the other groups (LT
group, 2.11, 95% CI, 1.36 to 2.86; MT group, 2.93, 95% CI,
1.94 to 3.92; P5NS).
Cardiovascular Morbidity During the Follow-up
Mean time of observation was 49 months, ranging from 6 to 96
months (median, 45 months). During the follow-up, 21
patients had a new cardiovascular event (11 with coronary
heart disease, myocardial infarction, or angina pectoris; 5 with
cerebrovascular disease, stroke, or transient ischemic attack; 4
with progressive heart failure; 1 with hypertensive emergency).
While no statistically significant difference between the two
groups with highest ambulatory BP, incidence of events was
significantly lower for the LT group (LT group, 2 events, 2.2
per 100 patient-years; MT group, 9 events, 9.5 per 100
patient-years; HT group, 10 events, 13.6 per 100 patient-
years). Similar results were observed when the comparison
between groups was performed by excluding patients with
previous cardiovascular events (LT group, 1 event, 1.3 per 100
patient-years; MT group, 6 events, 8.4 per 100 patient-years;
HT group, 7 events, 12.1 per 100 patient-years). The proba-
bility of event-free survival is shown in Fig 2. The comparison
of survival curves among the groups for the overall population
shows significant differences between the LT and MT groups
(log-rank P,.04), and between the LT and HT groups
(log-rank P,.006). No differences between MT and HT
groups were observed (log-rank P,.26). When only patients
without previous cardiovascular events were considered, dif-
ferences among groups remain (LT versus MT, P,.05; LT
versus HT, P,.02; MT versus HT, P,.37).
In the Cox analysis, the risk of cardiovascular events was
significantly higher for those patients who had previously
experienced cardiovascular events (RR, 2.47; 95% CI, 1.05 to
5.78, P,.04) and for subjects included in the HT group (RR,
6.20; 95% CI, 1.38 to 28.1, P,.02) (Table 4). The prognostic
value of ambulatory BP as an independent risk factor remains
even when patients who had suffered previous cardiovascular
events were removed from the analysis (RR, 8.76; 95% CI,
1.07 to 71.8, P5.05). In contrast, age, sex, left ventricular
hypertrophy in the ECG, SBP, and DBP office BP at the
beginning and at the time of the last evaluation and daytime
ambulatory SBP were not independent risk factors for morbid
cardiovascular events.
Discussion
In a group of 86 hypertensive patients with refractory hyper-
tension, defined as the finding of an office DBP $100 mm Hg
during the administration of an adequate combination of three
or more antihypertensive drugs, 21 cardiovascular events were
recorded during a mean follow-up of 49 months. The risk of
a cardiovascular event was significantly higher for the patients
who previously had experienced a cardiovascular event and for
patients who had a higher ambulatory BP at the time of
inclusion. The risk in relation to ambulatory BP values seems
to increase progressively from lowest values to highest. What-
Figure 1. Twenty-four-hour circadian BP profile in patients with
resistant hypertension grouped by ambulatory BP: LT group (E,
average of ambulatory during the activity DBP ,88 mm Hg,
n529), MT group (, average of ambulatory during the activity
DBP 88 to 97 mm Hg, n529), and HT group (f, average of
ambulatory during the activity DBP .97 mm Hg, n529). There
are significant differences in all hourly averages among groups.
Values are mean6SE.
Figure 2. Probability of event-free survival in patients with resis-
tant hypertension grouped by ambulatory BP: LT group (average
of ambulatory during the activity DBP ,88 mm Hg, n529), MT
group (average of ambulatory during the activity DBP 88 to
97 mm Hg, n529), and HT group (average of ambulatory during
the activity DBP .97 mm Hg, n529). The comparison of sur-
vival curves between the groups shows significant differences
between LT and MT groups (log-rank P,.04) and LT and HT
groups (log-rank P,.006). No differences between MT and HT
groups were observed (log-rank P,.26).
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ever the case, in the absence or in presence of a previous
cardiovascular event, ambulatory BP was an independent
marker of risk for new events. The data of the present study
show that ABPM is useful in stratifying the risk in patients with
refractory hypertension according to office BP measurements,
supporting the recommendations from the National and In-
ternational Consensus Meetings.10–20
The persistence of the differences between casual and
ambulatory BP observed in this study might be ascribable to
the persistence of the so-called “white-coat effect.”23–26 In this
sense, Gosse and coworkers24 retrospectively analyzed data
from 154 patients who had taken part in therapeutic trials.
These authors reported the presence of the white-coat effect in
the same percentage of patients both before and 3 months after
treatment. However, the authors stressed the low reproduc-
ibility of the magnitude of the white coat in individual patients,
where correlation coefficients of 0.45 for systolic and 0.32 for
diastolic pressure were shown. This study demonstrated that
the white-coat effect persists in hypertensive subjects even after
months of therapy and regardless of the class of drug used.
The differences between office and ambulatory BP and the
relation to the reduction in clinical BP during antihypertensive
treatment have recently been published by Parati and cowork-
ers25 in 266 patients treated with various antihypertensive drugs
and in 116 patients treated with placebo. They have concluded
that a considerable difference persists between clinical and
ambulatory BPs after several weeks of treatment but that the
magnitude of the differences is significantly attenuated with
time. Moreover, the reduction in clinical BP during treatment
was higher or lower in function to the magnitude of initial
differences between office and ambulatory BP. This observa-
tion is in agreement with our data, although no statistically
significant differences were present among the groups. The
data show that patients in LT group, with the greatest
difference between office BP and ambulatory BP, tended to
exhibit the greatest fall in office BP over time when compared
with patients in the other groups.
During the last several years, ABPM has been introduced
into hypertension research and in clinical practice on the basis
of two lines of evidence. First, that values of ambulatory BP are
more reproducible than their office BP counterparts, both in
normotensive and in hypertensive subjects, independent of the
age of subjects.27,28 Second, there is a very consistent body of
evidence from cross-sectional studies demonstrating that am-
TABLE 2. Baseline Clinical End-Organ Damage in Hypertensive Subjects Grouped by
Ambulatory BP
Lowest Tertile,
n529
(Daytime DBP
<88 mm Hg)
Middle Tertile,
n529
(Daytime DBP
88-97 mm Hg)
Highest Tertile,
n528
(Daytime DBP
>97 mm Hg)
Previous CV events 5 (17) 6 (21) 7 (25)
TIA or stroke 1 (3) 1 (3) 1 (4)
Coronary heart disease 2 (7) 4 (14) 4 (14)
Heart failure 2 (7) 1 (3) 2 (7)
ECG
Normal 15 (62) 18 (62) 12 (43)
LVH voltage 7 (24) 6 (21) 8 (29)
LVH voltage plus strain 7 (24) 5 (17) 8 (29)
Rx CT index
,0.50 24 (83) 19 (66) 19 (68)
0.50-0.55 5 (17) 8 (28) 7 (29)
.0.55 0 (0) 2 (7) 1 (4)
Funduscopy (Keith-Wagener)
0-I 25 (86) 11 (38) 7 (25)
II 4 (14) 14 (48) 20 (71)
III 0 (0) 4 (14) 1 (4)
Serum creatinine
,132 mmol/L 26 (90) 25 (86) 26 (93)
$132 mmol/L 3 (10) 4 (14) 2 (7)
Proteinuria
,1.0 g/24 hours 28 (97) 28 (97) 27 (96)
$1.0 g/24 hours 1 (3) 1 (3) 1 (4)
Total score* 2.3062.11 2.4162.39 2.6462.13
CV indicates cardiovascular; TIA, transient ischemic attack; LVH, left ventricular hypertrophy; and CT, cardiothoracic
index.
*Total score is the average of the individual score calculated according the criteria explained in the text.
Values are number of patients and the percentage between parentheses.
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bulatory BP correlates more closely than does office pressure
with target organ damage, as represented by left ventricular
hypertrophy5 and microalbuminuria in either hypertensive and
normotensive type 1 diabetes mellitus.29,30 Furthermore, Man-
cia et al31 in the SAMPLE study demonstrated that for
hypertensive patients with echographic left ventricular hyper-
trophy and in treatment with lisinopril, the reduction in left
ventricular mass was correlated to the fall in ambulatory BP but
not to the reduction in casual BP.
Prospective data relating ambulatory BP to cardiovascular
prognosis have been limited to two articles. The first, pub-
lished by Perloff and coworkers,7 included 751 patients and
evaluated daytime ambulatory BP as well as clinical BP
measurements during a follow-up of 5 years. This study
showed that the combination of ambulatory and clinical BP
values was a better predictor of the incidence of cardiovascular
events than was clinical BP alone. Although criticized on
several grounds, this was the first approach to the prognostic
value of ABPM. The second was published by Verdecchia and
coworkers,8 who followed 1187 hypertensive and 205 normo-
tensive men an women for an average of 3.2 years. The event
rate observed was similar in the normotensive and white-coat
hypertensives and was significantly higher in the sustained
hypertensives. The present study adds further information as to
the prognostic value of ABPM, in this case in patients with
refractory hypertension, a group with high cardiovascular risk.2
The results of this study deserve some commentary. First of
all, the averages of ambulatory BP at the beginning are a better
prognostic marker of cardiovascular events than are such other
well-known markers of risk as office BP during follow-up32
and left ventricular hypertrophy.33 The persistence of a marked
white-coat effect throughout the study and the high preva-
lence of left ventricular hypertrophy explains this result in our
study population. Second, the prognostic value of ambulatory
BP predicted not only the incidence of cardiovascular events
but also other end-organ damage. Occurrence of left ventric-
ular hypertrophy and/or proteinuria and the increment of
plasma creatinine values were more frequently in the HT
group than in the other groups during the observation period
(Table 3). Finally, ambulatory BP day/night ratio as an
estimate of circadian variability was not an independent marker
of risk among patients with refractory hypertension. A higher
cardiovascular risk has been reported in women with low BP
circadian variability, “nondippers,” than the risk in those with
“normal” BP circadian variability, “dippers.”8 The high BP
values maintained during the night, despite the presence of a
TABLE 3. End-Organ Damage and Cardiovascular Events Developed During the
Follow-up Period in Hypertensive Subjects Grouped by Ambulatory BP
Lowest Tertile,
n529
(Daytime DBP
<88 mm Hg)
Middle Tertile,
n529
(Daytime DBP
88-97 mm Hg)
Highest Tertile,
n528
(Daytime DBP
>97 mm Hg)
End-organ damage
ECG LVH 2 2 5
Serum creatinine .132 mmol/L 1 2 5
Proteinuria .1 g/24 hours 1 1 3
Total score 2.1161.90 2.9362.61 3.7062.22
Cardiovascular events
TIA or stroke 0 2 3
Angina or myocardial infarction 2 4 5
Progressive cardiac failure 0 2 2
Admission for hypertensive emergency 0 1 0
Total events 2 9 10
See Table 2 for abbreviations.
TABLE 4. Relative Risks for Cardiovascular Morbid Events Assessed by Cox Proportional Hazards Model
Covariate
Overall Population (n585) Patients Without CV Events (n567)
RR 95% CI P RR 95% CI P
Previous CV events, present vs absent 2.50 1.02-6.10 .045 z z z z z z z z z
Ambulatory BP
LT vs MT 3.69 0.79-17.33 .098 5.28 0.62-44.65 .127
LT vs HT 6.42 1.39-29.7 .017 8.75 1.06-72.15 .049
Age, ,60 y vs $60 y 1.28 0.43-3.76 .659 1.19 0.31-4.49 .801
Sex, F vs M 0.80 0.34-1.88 .602 0.94 0.28-3.12 .920
LVH ECG, present vs absent 1.53 0.61-3.88 .367 2.24 0.73-6.87 .156
LT indicates average of ambulatory during the activity DBP ,88 mm Hg; MT, average of ambulatory during the activity DBP 88-97 mm Hg; and HT, average of ambulatory
during the activity DBP .97 mm Hg. See Table 2 for other abbreviations.
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“normal” nocturnal BP fall, overcome the importance of the
extent of BP fall in refractory hypertensives.
It should be pointed out that the present study has several its
limitations. To begin with, the number of subjects was
relatively small, although as the subjects studied are a group
with high cardiovascular risk, the number of events recorded is
high enough to allow for comparisons between groups. Sec-
ond, antihypertensive drugs and their combinations were
variable during the follow-up because of the special character-
istics of the study group. The maintenance of the same
treatment during large periods could raise ethical conflicts.
Additionally, a lipid profile might help to explain our findings.
Nonetheless, only a small number of patients needed lipid-
lowering drugs, 3 in each group, and no differences in the
values of total cholesterol or triglycerides were present among
the groups at the time of inclusion. Finally, one aspect not
covered in the study was the performance of regular ABPM
during the follow-up to further assess the prognostic value of
this technique. It is known that lowering elevated BP results in
a remarkable reduction of hypertension-induced morbidity
and mortality and that the benefits of treatment are greatest for
those patients whose BP had been reduced the most.32
Whether or not ambulatory BP values throughout a long
follow-up period represent a more accurate prognostic tool
than office BP in evaluating refractory hypertensive patients
needs to be assessed in future studies.
In conclusion, higher values of ambulatory BP result in a more
accurate prognosis of future cardiovascular events in patients with
refractory hypertension than do casual BP values. Although more
studies are needed to better assess the prognostic value of ambu-
latory BP, the present data support the Consensus Meetings’
recommendation that ABPM be used to stratify cardiovascular
risk in patients with refractory hypertension.
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